Malignant transformation

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023

Retrieved on: 
Wednesday, April 12, 2023
Glioma, FGFR, Differentiable function, Brownstone, Isocitrate dehydrogenase, Acute myeloid leukemia, AML, Cancer, IDH2, IDH, IDH1, Malignant transformation, Chondrosarcoma, Cholangiocarcinoma, Vaccine

Mutant IDHs (“mIDHs”) cause accumulated 2-hydroxyglutarate, leading to blockage of cell differentiation, thereby inducing malignant transformation.

Key Points: 
  • Mutant IDHs (“mIDHs”) cause accumulated 2-hydroxyglutarate, leading to blockage of cell differentiation, thereby inducing malignant transformation.
  • Thus, simultaneous inhibition on both mIDH1 and mIDH2 may be a promising strategy to overcome resistance and improve clinical efficacy.
  • HMPL-306, a dual inhibitor of mIDH1/mIDH2, developed by HUTCHMED, is being evaluated in clinical trials ( NCT04272957 , NCT04762602 , NCT04764474 ).
  • HMPL-453, a highly selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays potent activity in FGFR-altered tumor models

BGI Genomics Partners with Zentya to Launch Fecal DNA Test for Colorectal Cancer in Slovakia

Retrieved on: 
Wednesday, March 29, 2023
Survival rate, DNA, Cancer, BGI Group, Genomics, Large intestine, Biomarker, Ministry, Colorectal cancer, Incidence, Conditional sentence, Genetic distance, Patient, Risk, Malignant transformation, Polyp, Ministry of Health, PCR, Dairy, Medical imaging

BRATISLAVA, Slovakia, March 29, 2023 /PRNewswire/ -- BGI Genomics is pleased to announce the launch of COLOTECTTM 1.0 in Slovakia, in collaboration with its partner, Zentya.

Key Points: 
  • BRATISLAVA, Slovakia, March 29, 2023 /PRNewswire/ -- BGI Genomics is pleased to announce the launch of COLOTECTTM 1.0 in Slovakia, in collaboration with its partner, Zentya.
  • COLOTECTTM 1.0 is one of the first-ever fecal DNA tests for colorectal cancer that is available in Slovakia.
  • It is a non-invasive fecal DNA test for detecting colorectal cancer and precancerous lesions.
  • Early detection is the key to the prevention of colorectal cancer and the improvement of survival rate because the progression of colorectal cancer development is generally very slow.

Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress

Retrieved on: 
Wednesday, November 30, 2022
Infection, COVID-19, Patient, SAN, Communication, PEM, SD, Congress, Lung, RECIST, Nausea, Malignant transformation, Cell, Risk, Epstein–Barr virus, Poster, Safety, Infectious mononucleosis, Therapy, Fatigue, Government, NPC, Oncology, HDAC, Creatinine, EBV, Neoplasm, Immunodeficiency, Nasopharyngeal carcinoma, Stomach, Plasma, Research, Webcast, Infrared spectroscopy correlation table, Lymphoma, European Society for Medical Oncology, Valganciclovir, Liver, Pharmaceutical industry, Vaccine

Key data reported in the abstract include:

Key Points: 
  • Key data reported in the abstract include:
    Nana-val was well tolerated with no dose limiting toxicities (DLTs) reported.
  • Plasma EBV DNA titers decreased or remained stable in both patients achieving SD, while rising in patients with progressive disease.
  • The company anticipates initiating the Phase 2 randomized expansion portion of the Phase 1b/2 trial in the second half of 2023.
  • This Phase 1b/2 trial ( NCT05166577 ) is an open-label, multinational trial evaluating Nana-val alone and in combination with pembrolizumab.

TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer

Retrieved on: 
Monday, November 7, 2022
Company, Solubility, Private Securities Litigation Reform Act, Research, Tumor microenvironment, Risk, Malignant transformation, MPM, GLOBE, Investor, Cell, Conference, HLA, Poster, Therapy, Truc, Nasdaq, Immunotherapy, TCR, Review, Annual report, U.S. Securities and Exchange Commission, Clinical trial, MSLN, Security (finance), Society, SITC, Patient, Society for Immunotherapy of Cancer, Vaccine, Pharmaceutical industry

These sMSLN levels are associated with tumor burden in malignant pleural/peritoneal mesothelioma (MPM).

Key Points: 
  • These sMSLN levels are associated with tumor burden in malignant pleural/peritoneal mesothelioma (MPM).
  • High, circulating levels of sMSLN have been implicated as a potential obstacle to maximizing the activity of anti-mesothelin therapies.
  • The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent ofhuman leukocyte antigens (HLA).
  • Any forward-looking statement included in this press release speaks only as of the date on which it was made.

gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma

Retrieved on: 
Wednesday, September 28, 2022
Cytokine release syndrome, OS, Safety, Nivolumab, HLA, Patient, Clinical trial, U.S. Securities and Exchange Commission, DLT, Nasdaq, CRS, Malignant transformation, Research, Large-cell lung carcinoma, Ipilimumab, PR, Risk, COVID-19, Ovary, Survival, NSCLC, Company, Growth, Cmax, Annual report, DCR, RECIST, Investor, DL, Cholangiocarcinoma, Ovarian cancer, Neoplasm, Population, MPM, Review, TCR, Progression-free survival, Tissue, Security (finance), GLOBE, Cancer, Infrared spectroscopy correlation table, Safety data sheet, Pancreatic cancer, Private Securities Litigation Reform Act, Therapy, Breast cancer, ORR, Metastasis, Cell, Cyber Safety Review Board, Secondary, Truc, PFS, Mesothelioma, Webcast, Pharmaceutical industry, Medical imaging, Vaccine

CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced positive topline results from the Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors, with some patients still being monitored for clinical response or stable disease.

Key Points: 
  • By BICR, the ORR was 21% among patients with malignant pleural/peritoneal mesothelioma (MPM) and 29% among those with ovarian cancer.
  • These are remarkable data in the context of solid tumors where there have been significant challenges with current CAR-T therapies.
  • The trial is enrolling patients with either mesothelin expressing non-small cell lung cancer (NSCLC), ovarian cancer, cholangiocarcinoma, or malignant pleural/peritoneal mesothelioma (MPM).
  • Mesothelin is a cell-surface glycoprotein highly expressed in a wide range of solid tumors, including malignant pleural/peritoneal mesothelioma, ovarian cancer, cholangiocarcinoma, breast cancer, pancreatic cancer and others.

Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth

Retrieved on: 
Monday, September 19, 2022
Adult, Risk, Time, Infectious mononucleosis, Shire, COVID-19, European Institute, Stomach, Business administration, Cell, PTC Therapeutics, Company, Population, Degenerative disease, Hematology, Private Securities Litigation Reform Act, HDAC, Industry, Therapy, Epstein–Barr virus, Patient, Infection, Government, Cancer, Nasopharyngeal carcinoma, CEO, University of Cambridge, Immunodeficiency, Goal, Nasdaq, Board of directors, Valganciclovir, Malignant transformation, General manager, Board, RNA, Silence Therapeutics, Biotechnology, Research, EBV, SEC, Marketing, Multimedia, Lymphoma, Communication, Mark's, INSEAD, Management, Pharmaceutical industry, Vaccine, Director

SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the succession of its President and Chief Executive Officer, Ivor Royston, M.D. to Mark Rothera, who was appointed as President and CEO and member of the Board of Directors, effective today. Dr. Royston will support the leadership transition and continue to serve as a member of the Board of Directors.

Key Points: 
  • to Mark Rothera, who was appointed as President and CEO and member of the Board of Directors, effective today.
  • Dr. Royston will support the leadership transition and continue to serve as a member of the Board of Directors.
  • Prior to joining Viracta, Mr. Rothera served as President and CEO of Silence Therapeutics, a clinical-stage organization focused on developing RNA therapies for hematology, cardiovascular and rare diseases.
  • Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.

Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors

Retrieved on: 
Wednesday, April 20, 2022
Patient, Head, HDAC, Immunodeficiency, Infectious mononucleosis, Moores Cancer Center, Population, Adult, Hannah, Stomach, Research, Immunotherapy, MD, NPC, Infection, Markey Cancer Center, Associate, PRMC, Department, Executive Committee, Valganciclovir, Cell, Malignant transformation, Standard of care, KOL, University of California, Nasdaq, Neoplasm, EBV, Nasopharyngeal carcinoma, Webcast, Division, Multimedia, University, Epstein–Barr virus, Risk, Therapy, Pharmacotherapy, Vaccine, Pharmaceutical industry

SAN DIEGO, April 20, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, will host a key opinion leader (KOL) webinar on Nana-val (nanatinostat and valganciclovir) for the treatment of advanced Epstein-Barr virus-positive (EBV+) solid tumors on Wednesday, April 27, 2022, at 11:00 AM EDT.

Key Points: 
  • Additionally, members of Viracta's management team will provide an overview of the ongoing Phase 1b/2 clinical trial evaluating Nana-val in patients with recurrent or metastatic NPC and other advanced EBV+ solid tumors.
  • Preclinical data supporting the use of Nana-val in solid tumors and the program's future outlook will also be discussed.
  • Following infection, the virus remains latent in a small subset of lymphatic cells for the duration of the patient's life.
  • Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

Toragen, Inc. Announces Appointment of Dr. Sandra Coufal, M.D. as CEO

Retrieved on: 
Wednesday, February 9, 2022
Biotechnology, Pharmaceutical, Health, Oncology, NASDAQ, Notre Dame, Digital technology, Multimedia, Medicine, UC San Diego Health, Division, Assistant, Doctor of Philosophy, Board, Head and neck cancer, Immune system, Genomics, Clinical trial, Radiation, FDA, Cervical cancer, Patient, CA, Investigational New Drug, University, Applied science, HPV, Chemistry, CEO, Biotechnology, Cancer, Food, Malignant transformation, Coufal, MD, Gastrointestinal cancer, Internal medicine, Pharmaceutical industry, Vaccine, Science, Inc., Torrey Pines

Since 2001, Dr. Coufal has also served as the Biomedical Advisor for the Genomics Institute of the Novartis Research Foundation.

Key Points: 
  • Since 2001, Dr. Coufal has also served as the Biomedical Advisor for the Genomics Institute of the Novartis Research Foundation.
  • She received her Bachelor of Science undergraduate degree from the University of Notre Dame and was designated a Notre Dame Scholar.
  • HPV associated cancers include Head and Neck Cancer, Cervical Cancer, and multiple other Genitourinary and Gastrointestinal Cancers.
  • Toragen is developing drugs designed to inhibit HPV oncogenes, the root cause of malignant transformation in these cancers.

Ivexsol Announces The Appointment Of Amitabha Deb, Ph.D.

Retrieved on: 
Tuesday, January 4, 2022
Multimedia, CSO, Arbutus Biopharma, Malignant transformation, Research, Cleveland Clinic, Virus, Senior, Intelligence, Management, Vaccine

LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- iVexSol, Inc., a lentiviral vector manufacturing company announces the appointment of Amitabha Deb, Ph.D. as Senior Vice President of Process Sciences and MS&T.

Key Points: 
  • LEXINGTON, Mass., Jan. 4, 2022 /PRNewswire/ -- iVexSol, Inc., a lentiviral vector manufacturing company announces the appointment of Amitabha Deb, Ph.D. as Senior Vice President of Process Sciences and MS&T.
  • Amitabha Deb, Ph.D. has 30 years of successful experience in the Biopharma industry.
  • As Senior Vice President of Process Sciences and MS&T at iVexSol, Amitabha will lead the efforts to develop closed system, automated processes for lentiviral production and purification using iVexSol's proprietary stable cell lines.
  • iVexSol, Inc. is a viral vector manufacturing company founded on a proprietary, next-generation, stable lentiviral vector production process that transforms the way these essential gene-delivery vehicles are made.

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021

Retrieved on: 
Monday, December 13, 2021
Infectious mononucleosis, T-cell lymphoma, Immunodeficiency, Communication, Research, Government, Valganciclovir, Patient, Time, Lymphoma, Risk, Stomach, Survival, Event, University of Colorado School of Medicine, Population, Nasopharyngeal carcinoma, Cell, Nasdaq, SAN, Society, EBV, Multimedia, Private Securities Litigation Reform Act, ASH, HDAC, Associate, Epstein–Barr virus, University, Toxic epidermal necrolysis, Infection, Malignant transformation, Cytopenia, Adult, COVID-19, Therapy, SEC, Industry, Pharmaceutical industry

Key data and conclusions from the ASH presentation:

Key Points: 
  • Key data and conclusions from the ASH presentation:
    As of the October 28, 2021, data cutoff, 55 patients were enrolled.
  • 75% (41/55) were refractory to their last therapy, and 96% (53/55) had exhausted all standard therapies (per Investigator).
  • The most commonly observed treatment emergent adverse events were reversible cytopenias, low grade creatinine elevations, and gastrointestinal symptoms.
  • Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.